MA45803B1 - Pyrido [3,4-b] indoles substitués pour le traitement de troubles du cartilage - Google Patents
Pyrido [3,4-b] indoles substitués pour le traitement de troubles du cartilageInfo
- Publication number
- MA45803B1 MA45803B1 MA45803A MA45803A MA45803B1 MA 45803 B1 MA45803 B1 MA 45803B1 MA 45803 A MA45803 A MA 45803A MA 45803 A MA45803 A MA 45803A MA 45803 B1 MA45803 B1 MA 45803B1
- Authority
- MA
- Morocco
- Prior art keywords
- pyrido
- treatment
- cartilage
- substituted indoles
- cartilage disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne des 9h-pyrido [3,4-b] indoles à substitution 8-aryle et 8-hétéroaryle de formule (i), dans laquelle a, e, g, r1 à r6 et r10 sont tels que définis dans les revendications, qui stimulent la synthèse de la chondrogenèse et de la matrice cartilagineuse et peuvent être utilisés dans le traitement de troubles et d'affections du cartilage dans lesquels une régénération du cartilage endommagé est souhaitée, par exemple des maladies articulaires telles que l'arthrose. L'invention concerne en outre des procédés de synthèse des composés de formule (i), leur utilisation comme composés pharmaceutiques et des compositions pharmaceutiques les comprenant.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306452.0A EP3318563A1 (fr) | 2016-11-07 | 2016-11-07 | Pyrido[3,4-b]indoles substitués pour le traitement de troubles du cartilage |
| PCT/EP2017/078026 WO2018083157A1 (fr) | 2016-11-07 | 2017-11-02 | Pyrido [3,4-b] indoles substitués pour le traitement de troubles du cartilage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA45803A1 MA45803A1 (fr) | 2020-05-29 |
| MA45803B1 true MA45803B1 (fr) | 2020-10-28 |
Family
ID=57286428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA45803A MA45803B1 (fr) | 2016-11-07 | 2017-11-02 | Pyrido [3,4-b] indoles substitués pour le traitement de troubles du cartilage |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US11130755B2 (fr) |
| EP (3) | EP3318563A1 (fr) |
| JP (1) | JP7046063B2 (fr) |
| KR (1) | KR102490199B1 (fr) |
| CN (1) | CN110382496B (fr) |
| AR (1) | AR110136A1 (fr) |
| AU (2) | AU2017353381B2 (fr) |
| BR (1) | BR112019007901A2 (fr) |
| CA (1) | CA3042332A1 (fr) |
| CL (1) | CL2019001251A1 (fr) |
| CO (1) | CO2019005090A2 (fr) |
| CR (1) | CR20190217A (fr) |
| DK (1) | DK3535263T3 (fr) |
| DO (1) | DOP2019000112A (fr) |
| EA (1) | EA038365B1 (fr) |
| EC (1) | ECSP19031458A (fr) |
| ES (1) | ES2837765T3 (fr) |
| HR (1) | HRP20201754T1 (fr) |
| HU (1) | HUE052187T2 (fr) |
| IL (1) | IL265982B (fr) |
| LT (1) | LT3535263T (fr) |
| MA (1) | MA45803B1 (fr) |
| MX (1) | MX2019005308A (fr) |
| MY (1) | MY189589A (fr) |
| PE (1) | PE20191032A1 (fr) |
| PH (1) | PH12019500997A1 (fr) |
| PT (1) | PT3535263T (fr) |
| RS (1) | RS61172B1 (fr) |
| SG (1) | SG11201903195YA (fr) |
| SI (1) | SI3535263T1 (fr) |
| TN (1) | TN2019000143A1 (fr) |
| TW (1) | TWI753966B (fr) |
| UY (1) | UY37473A (fr) |
| WO (1) | WO2018083157A1 (fr) |
| ZA (1) | ZA201902111B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3318563A1 (fr) | 2016-11-07 | 2018-05-09 | Sanofi | Pyrido[3,4-b]indoles substitués pour le traitement de troubles du cartilage |
| AU2018368790A1 (en) | 2017-11-20 | 2020-06-25 | Ichan School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| US11788064B2 (en) | 2018-01-05 | 2023-10-17 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
| CA3093340A1 (fr) | 2018-03-20 | 2019-09-26 | Icahn School Of Medicine At Mount Sinai | Composes inhibiteurs de kinase, compositions et procedes d'utilisation |
| US11485734B2 (en) | 2018-10-02 | 2022-11-01 | Northwestern University | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C) |
| US20220298135A1 (en) * | 2019-08-06 | 2022-09-22 | Domain Therapeutics | 5-heteroaryl-pyridin-2-amine compounds as neuropeptide ff receptor antagonists |
| CN114763347B (zh) * | 2021-01-15 | 2024-06-21 | 华东师范大学 | 一类用于诱导间充质干细胞向软骨分化的化合物及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4631149A (en) | 1983-07-25 | 1986-12-23 | University Of Illinois | Antiviral eudistomins from a marine tunicate |
| CA2140722A1 (fr) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline-thromboxane-synthetase |
| ECSP951529A (es) | 1995-09-05 | 1997-05-16 | Compuestos farmaceuticos | |
| EP1134221A1 (fr) * | 2000-03-15 | 2001-09-19 | Aventis Pharma Deutschland GmbH | Bêta-carbolines substituées comme inhibiteurs de lkB kinase |
| WO2001068648A1 (fr) | 2000-03-15 | 2001-09-20 | Aventis Pharma Deutschland Gmbh | Beta-carbolines substituees ayant une activite inhibitrice de l'ikb-kinase |
| DE60217532T8 (de) | 2001-11-07 | 2008-02-07 | Millennium Pharmaceuticals, Inc., Cambridge | Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas |
| FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
| JP4626613B2 (ja) | 2004-08-04 | 2011-02-09 | コニカミノルタホールディングス株式会社 | 有機エレクトロルミネッセンス素子 |
| EA015644B1 (ru) | 2006-08-25 | 2011-10-31 | Арес Трейдинг С.А. | Способ лечения заболеваний хряща |
| WO2008132454A1 (fr) | 2007-04-26 | 2008-11-06 | Ge Healthcare Limited | Carbolines et leur utilisation comme agents d'imagerie |
| WO2010038153A1 (fr) | 2008-10-01 | 2010-04-08 | The University Of British Columbia | Utilisation d'activateurs des facteurs de transcription sox pour stimuler la chondrogenèse |
| EP2455378A1 (fr) * | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Dérivés de carbazole et de carboline, et préparation et applications thérapeutiques associées |
| JP5854492B2 (ja) | 2011-02-24 | 2016-02-09 | 国立大学法人 岡山大学 | 軟骨細胞分化誘導促進剤 |
| UY35809A (es) | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
| JP2015107945A (ja) | 2013-12-05 | 2015-06-11 | 国立大学法人京都大学 | 神経新生に関する化合物及び医薬組成物 |
| EP3318563A1 (fr) | 2016-11-07 | 2018-05-09 | Sanofi | Pyrido[3,4-b]indoles substitués pour le traitement de troubles du cartilage |
-
2016
- 2016-11-07 EP EP16306452.0A patent/EP3318563A1/fr not_active Withdrawn
-
2017
- 2017-11-02 RS RS20201512A patent/RS61172B1/sr unknown
- 2017-11-02 DK DK17794307.3T patent/DK3535263T3/da active
- 2017-11-02 CR CR20190217A patent/CR20190217A/es unknown
- 2017-11-02 CN CN201780081846.4A patent/CN110382496B/zh active Active
- 2017-11-02 CA CA3042332A patent/CA3042332A1/fr active Pending
- 2017-11-02 TN TNP/2019/000143A patent/TN2019000143A1/en unknown
- 2017-11-02 MX MX2019005308A patent/MX2019005308A/es unknown
- 2017-11-02 MA MA45803A patent/MA45803B1/fr unknown
- 2017-11-02 KR KR1020197016225A patent/KR102490199B1/ko active IP Right Grant
- 2017-11-02 BR BR112019007901A patent/BR112019007901A2/pt unknown
- 2017-11-02 EP EP17794307.3A patent/EP3535263B1/fr active Active
- 2017-11-02 MY MYPI2019001925A patent/MY189589A/en unknown
- 2017-11-02 HU HUE17794307A patent/HUE052187T2/hu unknown
- 2017-11-02 US US16/347,386 patent/US11130755B2/en active Active
- 2017-11-02 AU AU2017353381A patent/AU2017353381B2/en active Active
- 2017-11-02 EA EA201991144A patent/EA038365B1/ru unknown
- 2017-11-02 WO PCT/EP2017/078026 patent/WO2018083157A1/fr unknown
- 2017-11-02 SG SG11201903195YA patent/SG11201903195YA/en unknown
- 2017-11-02 LT LTEP17794307.3T patent/LT3535263T/lt unknown
- 2017-11-02 PT PT177943073T patent/PT3535263T/pt unknown
- 2017-11-02 EP EP20198613.0A patent/EP3792262A1/fr active Pending
- 2017-11-02 SI SI201730476T patent/SI3535263T1/sl unknown
- 2017-11-02 ES ES17794307T patent/ES2837765T3/es active Active
- 2017-11-02 PE PE2019000879A patent/PE20191032A1/es unknown
- 2017-11-02 JP JP2019522912A patent/JP7046063B2/ja active Active
- 2017-11-03 TW TW106138038A patent/TWI753966B/zh active
- 2017-11-07 UY UY0001037473A patent/UY37473A/es not_active Application Discontinuation
- 2017-11-07 AR ARP170103083A patent/AR110136A1/es unknown
-
2019
- 2019-04-04 ZA ZA2019/02111A patent/ZA201902111B/en unknown
- 2019-04-11 IL IL265982A patent/IL265982B/en active IP Right Grant
- 2019-05-02 DO DO2019000112A patent/DOP2019000112A/es unknown
- 2019-05-06 PH PH12019500997A patent/PH12019500997A1/en unknown
- 2019-05-06 EC ECSENADI201931458A patent/ECSP19031458A/es unknown
- 2019-05-07 CL CL2019001251A patent/CL2019001251A1/es unknown
- 2019-05-17 CO CONC2019/0005090A patent/CO2019005090A2/es unknown
-
2020
- 2020-10-30 HR HRP20201754TT patent/HRP20201754T1/hr unknown
-
2021
- 2021-08-23 US US17/409,513 patent/US11827633B2/en active Active
- 2021-08-24 AU AU2021221468A patent/AU2021221468B2/en active Active
-
2023
- 2023-10-17 US US18/488,871 patent/US20240182469A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45803B1 (fr) | Pyrido [3,4-b] indoles substitués pour le traitement de troubles du cartilage | |
| MA37762B1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
| MA41179A (fr) | Composés inhibiteurs de parg | |
| MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA33920B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide | |
| MA41625A (fr) | Composés de benzazépine dicarboxamide | |
| MA31447B1 (fr) | Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1 | |
| MA42397B1 (fr) | 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b | |
| MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
| TN2010000230A1 (fr) | Agonistes nouveaux des recepteurs de glucocorticoides | |
| MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
| TN2009000551A1 (fr) | Nouveaux composes chimiques | |
| MA31521B1 (fr) | Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central | |
| MA32655B1 (fr) | Composés modulant sélectivement le récepteur cb2 | |
| MA38648A1 (fr) | Composés carboxamide de carbazole et de tétrahydrocarbazole substitués convenant comme inhibiteurs de kinases | |
| MA32798B1 (fr) | Acides naphtylacétiques | |
| MA37765A1 (fr) | Composés de pyrazole substitués utilisés comme antagonistes de lpar | |
| MA34308B1 (fr) | Triazolopyridines substituées | |
| MA35271B1 (fr) | Antagonistes de trpm8 et leur utilisation dans des traitements | |
| MA39582A1 (fr) | Composés de 6,7-dihydropyrazolo [1,5-?]pyrazin -4 (5h)-one et leur utilisation en tant que modulateurs négatifs allostériques des récepteurs métabotropiques du glutamate | |
| MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
| AU4038000A (en) | 4-substituted quinoline derivatives as gaba receptor ligands | |
| MA30540B1 (fr) | Derives de quinolines et compositions pharmaceutiques de ces derives. |